Labcorp EVP sells 762 shares in planned trade

LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported an open-market sale of Common Stock.

Rhea-AI Filing Summary

LABCORP HOLDINGS INC. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported an open-market sale of Common Stock. On June 8, 2026, she sold 762 shares at $263.89 per share in a transaction made under a pre-arranged Rule 10b5-1 trading plan. After this sale, she directly owns about 3,813.4574 shares of Labcorp common stock.

Insider Trade Summary 10b5-1

Net Seller: 762 shares

Net Sell 1 txn

Insider Kyle Kathryn W

Role EVP, Chief Legal Officer

Sold 762 shs ($201K)

Type	Security	Shares	Price	Value
Sale	Common Stock	762	$263.89	$201K

Holdings After Transaction: Common Stock — 3,813.4574 shares (Direct)

Footnotes (1)

1. F1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Key Figures

Shares sold: 762 shares Sale price: $263.89 per share Shares held after transaction: 3,813.4574 shares

3 metrics

Shares sold 762 shares Open-market sale of Labcorp Common Stock on June 8, 2026

Sale price $263.89 per share Price for the 762 Labcorp shares sold

Shares held after transaction 3,813.4574 shares Direct Labcorp Common Stock holdings after the sale

Key Terms

Rule 10b5-1, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 regulatory

"Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Labcorp (LH) disclose for Kathryn W. Kyle?

Labcorp disclosed that EVP and Chief Legal Officer Kathryn W. Kyle sold 762 shares of Common Stock. The open-market sale occurred on June 8, 2026 at $263.89 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.

How many Labcorp (LH) shares did Kathryn W. Kyle sell and at what price?

Kathryn W. Kyle sold 762 shares of Labcorp Common Stock at $263.89 per share. The transaction was reported as an open-market sale on June 8, 2026 and was conducted pursuant to a Rule 10b5-1 trading plan.

What are Kathryn W. Kyle’s Labcorp (LH) holdings after the reported sale?

Following the reported transaction, Kathryn W. Kyle directly holds about 3,813.4574 shares of Labcorp Common Stock. This figure reflects her position after selling 762 shares in the June 8, 2026 open-market sale under a Rule 10b5-1 plan.

Was the Labcorp (LH) insider sale by Kathryn W. Kyle under a Rule 10b5-1 plan?

Yes, the filing states the sale was made pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged under SEC rules and indicate the timing of transactions is scheduled in advance rather than based on current market information.

What role does Kathryn W. Kyle hold at Labcorp (LH) in this Form 4 filing?

Kathryn W. Kyle is identified as an officer of Labcorp, serving as Executive Vice President and Chief Legal Officer. The Form 4 reports her direct ownership of common shares and the June 8, 2026 open-market sale of 762 Labcorp shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 09:01 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kyle Kathryn W

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NORTH CAROLINA 27215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S(1)		762	D	$263.89	3,813.4574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

	/s/ Kathryn W. Kyle	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)